DACH1 and metabolic disease: Accordingly, suppression of DACH1 using hepatocyte-targeted siRNA strategies, a modality that has been approved for use in humans (63), may provide an integrated approach to the problem of hepatocyte-mediated perturbations in metabolic disease.